Breakthrough Melanoma Drug OK'd

September 2011
Chain Drug Review;9/26/2011, Vol. 33 Issue 16, p49
Trade Publication
The article reports on the approval of Zelboraf which is the first drug that treats advanced melanoma by targeting specific gene mutation by the Food and Drug Administration (FDA) in the U.S.


Related Articles

  • Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. Raedler, Lisa A. // Journal of Hematology Oncology Pharmacy;2016Specialissue, Vol. 6, p54 

    The article provides information approval of Imlygic (Talimogene Laherparepvec), an oncolytic viral therapy for treatment of Patients with Recurrent Melanoma, by U.S. Food and Drug Administration (FDA).

  • FDA approves Tafinlar, Mekinist for treatment of metastatic melanoma.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p26 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of dabrafenib and trametinib for treatment of melanoma patients.

  • FDA APPROVES FIRST TARGETED COMBINATION THERAPY FOR MELANOMA.  // Skin Cancer Foundation Journal;2014, Vol. 32, p11 

    The article reports on the U.S. Food and Drug Administration's approval of two drugs, dabrafenib and trametinib, as targeted combination therapy for advanced melanoma.

  • First oncolytic virus vaccine for advanced melanoma. MULLER, ALLISON A. // Pharmacy Today;Dec2015, Vol. 21 Issue 12, p32 

    The article focuses on the drug talimogene laherparepvec, the first oncolytic virus therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of recurrent melanoma.

  • REMS accompanies launch of new melanoma drug.  // Reactions Weekly;4/16/2011, Issue 1347, p4 

    The article reports on the approval of Yervoy (ipilimumab) by the U.S. Food and Drug Administration (FDA) on March 26, 2011 for the treatment of unresectable or metastatic melanoma and the launching of a Risk Evaluation and Mitigation Strategy (REMS) by the drug's developer Bristol-Myers Squibb...

  • CancerVax Treatment Goes Skin Deep. Webb, Marion // San Diego Business Journal;5/19/2003, Vol. 24 Issue 20, p1 

    Assesses the efficacy of Canvaxin drug in treating patients with melanoma disease. Approval of the U.S. Food and Administration on the distribution of the vaccine in the market; Risks of side effects; Forms of skin cancer.

  • FDA actions.  // Internal Medicine Alert;4/15/2011 Pharmacology Watch, p2 

    The article reports on the new drugs approved by the U.S. Food and Drug Administration including the vaccine Zostavax for the prevention of shingles, Ipilimumab for the treatment of late stage melanoma, and Belimumab for the treatment of systemic lupus erythematosus.

  • Vemurafenib Tablets (Zelborafâ„¢). Elliott, William T. // Internal Medicine Alert;10/29/2011, Vol. 33 Issue 20, p157 

    An abstract related to the U.S. Food and Drug Administration (FDA) review report conducted on the effectiveness of vemurafenib in patients with melanoma whose tumor expresses a gene mutation called BRAF V600E, is presented.

  • Merck gets key approval on melanoma drug. Strauss, Eric // njbiz;9/15/2014, Vol. 27 Issue 37, p3 

    The article reports that the U.S. Food and Drug Administration has approved drug manufacturer Merck's Keytruda (pembrolizumab) drug as treatment for patients with certain types of advanced melanoma as of mid-September 2014.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics